![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C11H16N2O |
Molar mass | 192.262 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Pozanicline (INN, [1] codenamed ABT-089) is a drug developed by Abbott, that has nootropic and neuroprotective effects. [2] [3] [4] Animal studies suggested it useful for the treatment of ADHD [5] and subsequent human trials have shown ABT-089 to be effective for this application. [6] It binds with high affinity subtype-selective to the α4β2 nicotinic acetylcholine receptors and has partial agonism to the α6β2 subtype, [7] [8] but not the α7 and α3β4 subtypes familiar to nicotine. It has particularly low tendency to cause side effects compared to other drugs in the class. [9] [10]
Pozanicline is synthesized from 2-methyl-3-hydroxypyridine and Boc-L-Prolinol through a dehydration reaction followed by deprotection of the nitrogen atom of prolinol [11]